Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Latest Biotechnology, Pharmaceutical and Healthcare News from Forbes

05:39 EDT 19th April 2014 | BioPortfolio

Here are the most relevant search results for "Forbes" found in our extensive news archives from over 250 global news sources.

More Information about Forbes on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Forbes for you to read. Along with our medical data and news we also list Forbes Clinical Trials, which are updated daily. BioPortfolio also has a large database of Forbes Companies for you to search.

Showing News Articles 1–25 of 468 from Forbes

Thursday 17th April 2014

What If Doctors Could Finally Prescribe Behavior Change?

This guest article is by Sean Duffy, CEO and Co-Founder, Omada Health Three out of four Americans will die of a disease that could be avoided—if only they could re-route their unhealthy habits. A new category of medicine, digital therapeutics, want...

Wednesday 16th April 2014

Should You Buy Inflation Protection For Long-Term Care Insurance?

Should you buy inflation protection for long-term care insurance? Absolutely. In fact, if you don’t think you can afford that extra coverage, you should probably rethink whether you should buy the insurance at all. The issue of inflation protection...

Dear Jenny McCarthy, Here’s How Many Lives Could Be Saved Cheaply By Making Vaccines More Widely Available

I usually prefer not to post graphics sent to me by groups that are trying to make their own political points. I’ll make an exception for Unicef. Some of the best evidence that vaccines are effective comes from the fact that we know what happen...

A Lucky Drug Made Pharmacyclics’ Robert Duggan A Billionaire. Will Long-Term Success Follow?

A combination of management smarts, providence and a breakthrough treatment made Robert Duggan a biotech billionaire. Long-term success? That's another story.

Wednesday 9th April 2014

Finally, Modest Progress Toward Long-Term Care Financing Reform

For the first time in years, there is hope that the U.S. can create a new model to help families finance long-term supports and services.  The solution isn’t yet visible, and lawmakers won’t address the issue any time soon. But a wide range of p...

Pushing Forward With Collaborative R&D Models In Biotech: Roche-Spero And Biogen-Ataxion

With today’s announcement of Roche’s deal with Spero Therapeutics LLC (here), and last month’s news regarding Biogen’s deal with Ataxion (here), we’ve added further momentum to our strategy of working closely with larger BioPharma partners...

Tuesday 8th April 2014

Cancer-Fighter Juno Therapeutics Hits The Pause Button On Trial After Patient Deaths

One of the most exciting new avenues in cancer research is the development of techniques to genetically re-engineer a patient’s own immune cells to destroy tumors. Several companies are racing to commercialize this technology. In the lead are ,...

Monday 7th April 2014

$5.6 Billion Questcor Deal Means High Drug Prices For Everybody

If you’re starting a biotechnology company and thinking of developing anything other than a super-high-priced medicine for a niche market, this morning’s news that is being bought by Dublin-based specialty pharma Mallinckrodt for $5.6 bil...

Raw Milk? A Fresh Glass Of Campylobacter And Salmonella. Yum.

A raw milk fad is sweeping the U.S., making many people deathly ill. Fans of raw milk are in denial about the benefits of pasteurization and seem stunningly ignorant of Louis Pasteur's achievement. Don't drink this stuff - and don't give it to your k...

Sunday 6th April 2014

Wow. Agios’ Experimental Leukemia Drug Makes Cancer Undetectable In Three Patients

Agios, a biotechnology company based in Cambridge, Mass., has seemed in some ways a sign of the overexcitement of the recent biotech boom. After all, the company, despite an experienced management team, a July public stock offering that raised more t...

Pfizer Breast Cancer Drug Results “As Impressive As I’ve Ever Seen,” Researcher Says

An experimental medicine developed by slowed the pace of advanced breast cancer, doubling the amount of time that patients could live without their tumors advancing. Women receiving the pill, called palbociclib, with other treatments went 20.2 months...

Thursday 3rd April 2014

Will Pfizer Unveil A Breast Cancer Blockbuster This Sunday?

A decade ago, , then the world’s largest drug company, sold three of the 10 biggest-grossing medicines in the United States. Now, it doesn’t boast one. analysts think a study of a breast cancer medicine being presented at a medical meeting in San...

Wednesday 2nd April 2014

Tradeoffs and Timing: IPO vs. M&A Decision-Making In Biotech

In light of the continued interest in biotech IPOs by the capital markets, there’s probably not a venture-backed biotech boardroom that hasn’t been discussing the merits of going public. Whether warranted or not, taking a company public via an IP...

The Real Value Of ObamaCare Has Nothing To Do With Enrollment

The noisy debate over how many people have gotten health insurance under the Affordable Care Act misses the point. Yes, reducing the number of uninsured was one goal of the ACA. But only one. The law’s most enduring legacy will come from its his...

Monday 31st March 2014

Glaxo’s Utter Stinkbomb Of A Drug

Usually, saying that an experimental medicine stinks is a metaphorical statement. You know, its efficacy is marginal, or there are serious side effects. Not so for darapladib, results of which were presented at the annual meeting of the American Coll...

Push Comes To Shove: Gilead’s $1,000 Pill Could Hurt Insurer Earnings

$1,000-a-day hepatitis C drug, Sovaldi, could hurt the bottom lines of insurance companies, according to an analysis conducted by Leerink, the investment bank. Sovaldi is having one of the most successful drug launches ever, and could generate $1.5 b...

Thursday 27th March 2014

Biotech Stocks: Seeing Rainbows, Missing The Rain

The Nasdaq iShares Biotechnology Index, by YCharts This week’s 10% drop in the Nasdaq iShares’ Biotechnology Index — not to mention the fact that biotech , after a torrid two years, are up less than 4%  year-to-date — has investors w...

Glaxo Effort To Verify Gene Data Represents Step For Open Science

GlaxoSmithKline’s efforts to fund a 50-person effort with two top universities to verify that the proteins it is picking as targets for drugs are actually involved in the diseases the company hopes to treat are a big example of the Big Pharma dropp...

Wednesday 26th March 2014

How A New Alzheimer’s Test Could Kill Long-Term Care Insurance — Or Make It Cheaper

A team of researchers at and six other medical centers has developed a simple blood test  they say can predict, with 90 percent accuracy, whether an individual will develop Alzheimer’s Disease within 2-3 years.  If it works as advertised, such a...

Gene Therapy’s Big Comeback

After decades of experimentation and failure is gene therapy finally ready for prime time? Investors certainly think so.

Monday 24th March 2014

One Of Pharma’s Biggest Enemies Goes After The Future’s Best-Selling Drug

Over the past two decades, U.S. Representative Henry Waxman has given the drug industry good reason to fear him. Waxman (D.-California) humiliated in open hearings by publicizing sales training materials that indicated the company had instructed its...

Sunday 23rd March 2014

Why Google Flu Is A Failure

Google Flu is an attempt by Google to track the spread of the flu virus by following individuals' searches for flu-related topics. It was announced with great fanfare in 2009. Now, five years later, it's a spectacular failure.

Friday 21st March 2014

Transformational Late Stage Drugs Delivered Through Deal-Making

Today’s biopharma industry has a richer and more exciting late stage pipeline of compelling new therapeutics than its had in years, drawing lots of enthusiasm from analysts and investors.  Goldman Sachs (GS) recently published a report on the “1...

Wednesday 19th March 2014

We All Want To Live At Home In Old Age, But Know Nothing About the Quality of Care We’ll Get There

The other day, I wrote about a troubling report on the high likelihood of falls or medication errors in skilled nursing facilities. The problem is real and serious, but at least we can measure it– which is a first step towards fixing it. In con...

IBM’s Watson Attempts To Tackle The Genetics Of Brain Cancer

This morning, and the New York Genome Center announced a partnership to test whether Watson, the computer that won on Jeopardy, can sift through the genomes of cancer patients and help doctors pick drugs. This effort could hold the key to making DNA...

Search BioPortfolio:

News Quicklinks